25.10.2012 - Fujifilm Diosynth has partnered with British Piramal Healthcare to produce Antibody Drug Conjugates.
Fujifilm Diosynth Biotechnologies has entered into a strategic alliance with Piramal Healthcare UK Ltd (Billingham, UK) in the emerging market of antibody drug conjugates (ADCs), that is antibodies chemically coupled to a small molecule toxin. Under the terms of the contract development and manufacture agreement, Piramal will bring in its expertise in antibody drug conjugation while Fujifilm Diosynth Biotechnologies will provide its experience in manufacturing biopharmaceuticals in mammalian cell culture. The companies said the deal will allow customers to benefit from the experience and assets of both organisations, while simplifying the supply chain and vendor management relationships, leading to shorter time to clinic.
The partnership covers work on more than 150 biopharmaceuticals and over 300 batches of ADCs spanning over more than 30 different NCEs, including the world's only FDA-approved ADC, Seattle Genetics’ Adcetris. Fujifilm Diosynth Biotechnologies recently announced an expansion of its cGMP manufacturing facilities at both its RTP, USA and Billingham, UK sites.
26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.
24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.
23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.
17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.
13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.
13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.
10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.
10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.